Prediction Markets

Will the US Food and Drug Administration approve at least one new molecular entity for the treatment of Alzheimer's disease in 2026?

Will the US Food and Drug Administration approve more than 45 new molecular entities in 2026?

Will the European Medicines Agency approve more than 40 new active substances in 2026?

Will the phase 3 clinical trial of olpasiran (LY3473329) for reduction of major adverse cardiovascular events meet its primary endpoint by January 31, 2027?

Will the phase 3 clinical trial of NTLA-2001 (NCT04601051) for hereditary transthyretin amyloidosis meet its primary endpoint by June 30, 2027?

Will the World Health Organization prequalify a new diagnostic test for tuberculosis by July 24, 2026?

Will the European Medicines Agency grant Priority Medicines (PRIME) designation for a new treatment for amyotrophic lateral sclerosis by July 24, 2026?

Will the Phase 3 trial of 'GB-005' for moderate-to-severe acne meet its co-primary endpoints in a company press release by July 24, 2026?

Will the FDA approve the first vaccine for Epstein-Barr virus by July 24, 2026?